Baidu
map
BMJ OPEN DIAB RES CA 润色咨询

BMJ Open Diabetes Research & Care

出版年份：2014 年文章数：1047 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0<br>经验分享：审稿3轮，历时6个月发表。RCT。本来想&gt;5，2020年&lt;4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：糖尿病;内分泌;T2DM<br>经验分享：官方自己的数据：<br>Acceptance rate 58%<br>Mean time from submission to first decision for all papers 32 days<br>Mean time from submission to first decision for reviewed papers 41 days<br>Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2023-02-02 ms2145678728954567 来自江苏省

    投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0<br>经验分享：审稿3轮，历时6个月发表。RCT。本来想&gt;5，2020年&lt;4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：糖尿病;内分泌;T2DM<br>经验分享：官方自己的数据：<br>Acceptance rate 58%<br>Mean time from submission to first decision for all papers 32 days<br>Mean time from submission to first decision for reviewed papers 41 days<br>Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2022-10-23 ms7000000324097631

    来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0<br>经验分享：审稿3轮，历时6个月发表。RCT。本来想&gt;5，2020年&lt;4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：糖尿病;内分泌;T2DM<br>经验分享：官方自己的数据：<br>Acceptance rate 58%<br>Mean time from submission to first decision for all papers 32 days<br>Mean time from submission to first decision for reviewed papers 41 days<br>Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-10-02 1df0083fm15(暂无匿称)

    审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0
    经验分享：审稿3轮，历时6个月发表。RCT。本来想>5，2020年<4，不过有前景。主编曾获ADA大奖。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0<br>经验分享：审稿3轮，历时6个月发表。RCT。本来想&gt;5，2020年&lt;4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：糖尿病;内分泌;T2DM<br>经验分享：官方自己的数据：<br>Acceptance rate 58%<br>Mean time from submission to first decision for all papers 32 days<br>Mean time from submission to first decision for reviewed papers 41 days<br>Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2019-11-28 hpchensd

    有在这杂志投稿的么

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0<br>经验分享：审稿3轮，历时6个月发表。RCT。本来想&gt;5，2020年&lt;4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：糖尿病;内分泌;T2DM<br>经验分享：官方自己的数据：<br>Acceptance rate 58%<br>Mean time from submission to first decision for all papers 32 days<br>Mean time from submission to first decision for reviewed papers 41 days<br>Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-06-02 lovetcm

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：糖尿病;内分泌;T2DM
    经验分享：官方自己的数据：
    Acceptance rate 58%
    Mean time from submission to first decision for all papers 32 days
    Mean time from submission to first decision for reviewed papers 41 days
    Mean time from acceptance to publication 26 days

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2112786, encodeId=8c662112e86c9, content=投了一篇基础的文章，一月九号投的，截止到2月2日，还是awaiting reviewer selection, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5iaIECdZHPwfIYS36E99fzevBfbCPSZVgPm6AeQXkLRibVsfNeawKmWBMd5xEe6BlFFU1SiaJxJOJg/132, createdBy=d0712191887, createdName=ms2145678728954567, createdTime=Thu Feb 02 20:08:26 CST 2023, time=2023-02-02, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2095553, encodeId=d8fa2095553d3, content=来攒人品啦 2022-06-04投稿 2022-06-23大修 2022-08-21 小修 2022-09-01接受 返修一件很中肯，投稿速度已经算快了，感恩🙏, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fca8249791, createdName=ms7000000324097631, createdTime=Sun Oct 23 17:03:22 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889651, encodeId=c6658896519a, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:3000.0<br>经验分享：审稿3轮，历时6个月发表。RCT。本来想&gt;5，2020年&lt;4，不过有前景。主编曾获ADA大奖。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Fri Oct 02 08:00:02 CST 2020, time=2020-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580612, encodeId=37095806129f, content=有在这杂志投稿的么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/15/07ee8fa79cbc2897824c21ee81488159.jpg, createdBy=890e84382, createdName=hpchensd, createdTime=Thu Nov 28 00:00:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601151, encodeId=4be7601151f0, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：糖尿病;内分泌;T2DM<br>经验分享：官方自己的数据：<br>Acceptance rate 58%<br>Mean time from submission to first decision for all papers 32 days<br>Mean time from submission to first decision for reviewed papers 41 days<br>Mean time from acceptance to publication 26 days, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=232, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jun 02 09:48:45 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586185, encodeId=9129586185d5, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：审稿速度比较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/tMzlXA6gXGFQicoOYY4VGTxrialYye2r0RlPkX20iaibdrJ9zX3ff5oFHKfPfEceI5ZZVfiazP6QShRLRYVwiaqGYibUQ/132, createdBy=1fea2318128, createdName=Omega 3, createdTime=Sun Mar 08 22:19:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-03-08 Omega 3

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享：审稿速度比较慢。

    0

共7条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map